Metropolitan Life Insurance Co NY decreased its holdings in shares of Option Care Health, Inc. (NASDAQ:OPCH – Get Rating) by 84.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,734 shares of the company's stock after selling 52,197 shares during the quarter. Metropolitan Life Insurance Co NY's holdings in Option Care Health were worth $278,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in OPCH. State Street Corp lifted its holdings in Option Care Health by 8.4% during the 4th quarter. State Street Corp now owns 4,406,306 shares of the company's stock worth $125,315,000 after purchasing an additional 341,158 shares in the last quarter. Marshall Wace LLP bought a new position in Option Care Health in the fourth quarter valued at $85,991,000. Nuveen Asset Management LLC raised its position in Option Care Health by 1.8% during the fourth quarter. Nuveen Asset Management LLC now owns 2,937,263 shares of the company's stock valued at $83,536,000 after purchasing an additional 53,279 shares in the last quarter. Geode Capital Management LLC lifted its stake in Option Care Health by 7.1% during the fourth quarter. Geode Capital Management LLC now owns 2,688,710 shares of the company's stock worth $76,466,000 after purchasing an additional 177,890 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Option Care Health by 8.2% during the 1st quarter. JPMorgan Chase & Co. now owns 2,200,320 shares of the company's stock valued at $62,840,000 after purchasing an additional 167,399 shares during the last quarter. Hedge funds and other institutional investors own 92.58% of the company's stock.

Analyst Ratings Changes

Several analysts have issued reports on the company. Lake Street Capital upped their target price on Option Care Health from $35.00 to $45.00 in a research note on Thursday, July 28th. Barrington Research increased their target price on shares of Option Care Health from $33.00 to $37.00 and gave the company an "outperform" rating in a report on Thursday, July 28th. The Goldman Sachs Group lifted their price target on Option Care Health from $31.00 to $40.00 and gave the stock a "buy" rating in a research note on Monday, August 22nd. Finally, TheStreet upgraded shares of Option Care Health from a "c+" rating to a "b" rating in a report on Monday, June 6th.

Insider Transactions at Option Care Health

Option Care Health Trading Up 2.4 %

OPCH opened at $32.50 on Thursday. Option Care Health, Inc. has a one year low of $21.32 and a one year high of $35.57. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.58 and a quick ratio of 1.16. The business has a 50 day simple moving average of $31.91 and a two-hundred day simple moving average of $29.20. The firm has a market capitalization of $5.91 billion, a price-to-earnings ratio of 33.51, a PEG ratio of 2.86 and a beta of 1.34.

Option Care Health (NASDAQ:OPCH – Get Rating) last announced its earnings results on Wednesday, July 27th. The company reported $0.19 EPS for the quarter, missing analysts' consensus estimates of $0.22 by ($0.03). The business had revenue of $980.80 million for the quarter, compared to the consensus estimate of $940.93 million. Option Care Health had a net margin of 4.71% and a return on equity of 12.11%. Option Care Health's revenue was up 14.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.18 EPS. Analysts predict that Option Care Health, Inc. will post 0.78 EPS for the current year.

Option Care Health Profile

(Get Rating)

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.

Featured Stories

• Get a free copy of the StockNews.com research report on Option Care Health (OPCH)
• 3 High Margin Chipmakers Bound to Recover
• 3 Solar Stocks That Will Benefit From the Biden Tariff Holiday
• REV Group Has A Deep Moat In The World Of EVs
• Is G-III Apparel Group, Ltd. A Value Trap?
• Bank Of America Sees Upside In These 2 European Alcohol Stocks

Receive News & Ratings for Option Care Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Option Care Health and related companies with MarketBeat.com's FREE daily email newsletter.